AMLX - AMLX Class Action Alert: Robbins LLP Reminds Investors of Pending Lead Plaintiff Deadline – April 9 2024 – in Amylyx Pharmaceuticals Inc. Class Action | Benzinga
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) --
Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) securities between November 11, 2022 and November 8, 2023. Amylyx is a commercial-stage biotechnology company that engages in the discovery and development of treatments for amyotrophic lateral sclerosis ("ALS") and other neurodegenerative diseases. The Company's products include, among others, AMX0035 (commercially referred to as "RELYVRIO" in the U.S.) for the treatment of ALS in adults in the U.S.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: According to the complaint, during the class period, defendants misled investors regarding RELYVRIO's commercial prospects. Specifically, defendants failed to disclose that: (i) patients were discontinuing treatment with RELYVRIO after six months; ...